Continuation of enzalutamide after progression of docetaxel treated metastatic castration-resistant prostate cancer

Although androgen deprivation therapy is typically given long-term in men with metastatic prostate cancer, second-generation hormone therapies are generally discontinued before the subsequent line of treatment. The multinational phase 3b PRESIDE study evaluated continuation of enzalutamide after progression of metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel and prednisolone. Median progression-free survival was 9.5 months with enzalutamide versus 8.3 months with placebo (HR 0.72; p=0.027). The authors conclude that continuing enzalutamide with docetaxel plus androgen deprivation therapy delayed time to progression compared with docetaxel plus androgen deprivation therapy alone, supporting the hypothesis that enzalutamide maintenance could control persistent androgen-dependent clones in men with mCRPC who progress after treatment with enzalutamide alone.